Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil can be used with isopropyl alcohol to create topical spironolactone. Spironolactone may dissolve better in ethanol or propylene glycol.

Minokem-N's composition is unclear, with concerns about unlisted hydrocortisone. Users discuss alternatives like AloATM, which lacks soothing agents, and the challenges of verifying ingredients.

RU-58841 does not dissolve well in common Minoxidil solutions due to water content, requiring a 70/30 ethanol/propylene glycol mix. Users report using separate solutions for RU-58841 and finasteride/Minoxidil for better results.

The user is considering storing Fluridil in a different container for easier application and asks if it can be mixed with Minoxidil or if hair styling products will affect its potency. They also inquire about the order and timing of applying these hair loss treatments.

A user is asking if a new hair product, Cypress Premium Vials Energy and Cypress Premium Shampoo Energy, could be dangerous or worsen their hair condition. The product contains various ingredients including water, alcohol, menthyl lactate, and several extracts.

A user experimented with applying hot water to their scalp to potentially stimulate hair growth, noting reduced dandruff but uncertain hair loss results. They started this method due to side effects from minoxidil and are considering taking a break to observe changes.

User is using minoxidil with tretinoin 0.025% and experiencing peeling and burning on the scalp. They are unsure if it's effective or if they are using it too frequently.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

Using roll-on bottles for applying minoxidil and RU58841 improves application efficiency and reduces product waste. Topical treatments are used continuously, except on microneedling days.

The user is experimenting with topical melatonin for hair loss by dissolving melatonin tablets in a solution, but is having trouble with dissolution and is curious about others' methods of application and any effects on energy levels. They mention considering mixing with minoxidil but have not done so, and suggest that melatonin is best used at night.

Making a hair solution using RU58841 from raw powder. Users humorously compare the process to a science experiment.

Topical finasteride in a liposomal formulation reduces systemic absorption compared to ethanol solutions. The user is seeking sources for such products, noting that popular options like morr-f are not liposomal.

The conversation is about using DIY deoxyribose topical and botox injections for hair loss. The user is experimenting with these treatments and believes the science is strong.

The conversation discusses using Rogain foam as a solvent for topical finasteride due to an allergy to propylene glycol. The foam's ingredients, including alcohol SD 40B, are considered suitable for dissolving finasteride for easier application without skin irritation.

A user mixed 3g of RU58841 with Kirkland Minoxidil and noticed a gooey precipitate forming. They are seeking advice on what went wrong.

The conversation is about making topical finasteride using stemoxydine as a carrier. The user is considering buying Redken Cerafill Hair Re-Densifying Treatment (Stemoxydine) 90ml for this purpose.

A user bought questionable RU58841 powder from AliExpress and seeks a way to test its composition in Europe. Another user suggests using Janoshik for testing.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

Store finasteride powder in a cool, dry place. RU58841 needs to be stored in the freezer.

A user suggests making a potent sulforaphane topical to degrade DHT and promote hair growth. Another user notes that sulforaphane's low molecular weight might also lower systemic DHT.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The conversation is about making a 20mg/ml RU58841 solution for hair loss treatment using ethanol and propylene glycol. The user receives advice on calculating the correct amount of RU58841 powder needed.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

The conversation is about creating homemade topical melatonin for hair loss, with one person suggesting adding melatonin to stemoxydine as a potential treatment.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.